Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug

  • Seres Therapeutics Inc MCRB announced confirmatory results from ECOSPOR IV, an open-label study for SER-109 to prevent recurrent C. difficile infection (rCDI). 
  • The overall safety profile observed in ECOSPOR IV through 24 weeks indicated that SER-109 was well tolerated.
  • The ECOSPOR III and ECOSPOR IV studies conclude the SER-109 Phase 3 development program.
  • In ECOSPOR IV, subjects treated with SER-109 had a recurrence rate of 8.7% at eight weeks, which indicates a 91.3% sustained clinical response. 
  • Also Read: Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis.
  • At 24 weeks, 13.7% of all subjects treated with SER-109 had CDI recurrence.
  • The company noted that less than 9% of treated patients experienced recurrence within eight weeks of treatment.
  • Seres has initiated the rolling submission of the SER-109 BLA and anticipates completing the BLA submission by mid-2022. It anticipates a potential launch of SER-109 in 1H of 2023.
  • Price Action: MCRB shares are up 11.6% at $3.61 during the market session on the last check Tuesday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.